Nonalcoholic fatty liver disease and the epidemic of obesity

Article Type
Article
Changed
Mon, 10/08/2018 - 11:14
Display Headline
Nonalcoholic fatty liver disease and the epidemic of obesity
Author(s)
Rochelle Collantes, MD, MPH
Janus P. Ong, MD
Zobair M. Younossi, MD, MPH
Article PDF
content_71_657.pdf
Author and Disclosure Information

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Issue
Cleveland Clinic Journal of Medicine - 71(8)
Publications
Cleveland Clinic Journal of Medicine
Topics
Gastroenterology
Obesity
Page Number
657-664
Sections
Reviews
Author(s)
Rochelle Collantes, MD, MPH
Janus P. Ong, MD
Zobair M. Younossi, MD, MPH
Author(s)
Rochelle Collantes, MD, MPH
Janus P. Ong, MD
Zobair M. Younossi, MD, MPH
Author and Disclosure Information

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Author and Disclosure Information

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Article PDF
content_71_657.pdf
Article PDF
content_71_657.pdf
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Page Number
657-664
Page Number
657-664
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Topics
Gastroenterology
Obesity
Article Type
Article
Display Headline
Nonalcoholic fatty liver disease and the epidemic of obesity
Display Headline
Nonalcoholic fatty liver disease and the epidemic of obesity
Sections
Reviews
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C

Article Type
Article
Changed
Tue, 10/30/2018 - 12:14
Display Headline
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C
Anemia, neutropenia, and thrombocytopenia
Author(s)
Janus P. Ong, MD
Zobair M. Younossi, MD, MPH
Article PDF
content_71_Suppl_3_SI-17.pdf
Author and Disclosure Information

Janus P. Ong, MD
Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Va

Zobair M. Younossi, MD, MPH
Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Va

Correspondence: Zobair Younossi, MD, MPH, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042; e-mail: zobair.younossi@inova.com

Dr. Ong reported that he has no commercial affiliations or interests that pose a potential conflict of interest with this article.

Dr. Younossi reported that he has received grant or research support from, serves as a consultant to, and is on the speakers’ bureaus of the Roche, Schering-Plough, Amgen, Ortho Biotech, and Axcan corporations.

Publications
Cleveland Clinic Journal of Medicine
Page Number
S17-S21
Author(s)
Janus P. Ong, MD
Zobair M. Younossi, MD, MPH
Author(s)
Janus P. Ong, MD
Zobair M. Younossi, MD, MPH
Author and Disclosure Information

Janus P. Ong, MD
Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Va

Zobair M. Younossi, MD, MPH
Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Va

Correspondence: Zobair Younossi, MD, MPH, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042; e-mail: zobair.younossi@inova.com

Dr. Ong reported that he has no commercial affiliations or interests that pose a potential conflict of interest with this article.

Dr. Younossi reported that he has received grant or research support from, serves as a consultant to, and is on the speakers’ bureaus of the Roche, Schering-Plough, Amgen, Ortho Biotech, and Axcan corporations.

Author and Disclosure Information

Janus P. Ong, MD
Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Va

Zobair M. Younossi, MD, MPH
Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Va

Correspondence: Zobair Younossi, MD, MPH, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042; e-mail: zobair.younossi@inova.com

Dr. Ong reported that he has no commercial affiliations or interests that pose a potential conflict of interest with this article.

Dr. Younossi reported that he has received grant or research support from, serves as a consultant to, and is on the speakers’ bureaus of the Roche, Schering-Plough, Amgen, Ortho Biotech, and Axcan corporations.

Article PDF
content_71_Suppl_3_SI-17.pdf
Article PDF
content_71_Suppl_3_SI-17.pdf
Anemia, neutropenia, and thrombocytopenia
Anemia, neutropenia, and thrombocytopenia
Page Number
S17-S21
Page Number
S17-S21
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Article Type
Article
Display Headline
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C
Display Headline
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C
Citation Override
Cleveland Clinic Journal of Medicine 2004 May;71(suppl 3):S17-S21
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media
Subscribe to Janus P. Ong, MD